Fanny BUREL-VANDENBOS

Prof. Dr. Fanny BUREL-VANDENBOS

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CPCaroline Papin-Michault
Caroline Papin-Michault
CBChristelle Bonnetaud
Christelle Bonnetaud
MDMaxime Dufour
Maxime Dufour
FAFabien Almairac
Fabien Almairac
MCMickael Coutts
Mickael Coutts
FBFanny BUREL-VANDENBOS
Fanny BUREL-VANDENBOS
Positron emission tomography using radiolabeled amino acid (PET-AA) appears to be promising in distinguishing between recurrent tumour and radionecrosis in the follow-up of brain metastasis (BM). The amino acid transporter LAT1 and its cofactor CD98, which are involved in AA uptake, have never been investigated in BM. The aim of our study was to determine and compare the expression of LAT1 and CD98 in BM and in non-tumoral brain tissue (NT). The expression of LAT1 and CD98 were studied by immunohistochemistry in 67 BM, including 18 BM recurrences after radiotherapy, in 53 NT, and in 13 cases of patients with previously irradiated brain tumor and investigated by [18F] FDOPA-PET. LAT1 and CD98 expression were detected in 98.5% and 59.7% of BM respectively and were significantly associated with BM tissue as compared to NT (p<0.001). LAT1 expression in recurrent BM was significantly increased as compared to newly occurring BM. Ten cases investigated by [18F] FDOPA-PET corresponding to recurrent BM displayed significant [18F] FDOPA uptake and LAT1 overexpression whereas three cases corresponding to radionecrosis showed no or low uptake and LAT1 expression. LAT1 expression level and [18F] FDOPA uptake were significantly correlated. In conclusion, we hypothesized that BM may overexpress the AA transporter LAT1. We have shown that LAT1 overexpression was common in BM and was specific for BM as compared to healthy brain. These results could explain the specific BM uptake on PET-AA.

20 October 2012 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
FBFanny BUREL-VANDENBOS
Fanny BUREL-VANDENBOS
DADamien Ambrosetti
Damien Ambrosetti
MCMichael Coutts
Michael Coutts
FPFlorence Pedeutour
Florence Pedeutour

1 May 2015 in Journal of Autoimmunity
Verified
Journal Article
Closed access
EGEtienne Ghrenassia
Etienne Ghrenassia
NMNihal Martis
Nihal Martis
JBJulien Boyer
Julien Boyer
FBFanny BUREL-VANDENBOS
Fanny BUREL-VANDENBOS
AMArsène Mekinian
Arsène Mekinian
PCPaul Coppo*
Paul Coppo*

1 January 2021 in Neuro-Oncology Advances
Verified
Journal Article
Open access
PDF file
TPThiebaud Picart
Thiebaud Picart
MBMarc Barritault
Marc Barritault
DPDelphine Poncet
Delphine Poncet
LBLise-Prune Berner
Lise-Prune Berner
CICristina Izquierdo
Cristina Izquierdo
FDFrancois Ducray
Francois Ducray
Diffuse hemispheric gliomas, H3 G34-mutant (DHG H3G34-mutant) constitute a distinct type of aggressive brain tumors. Although initially described in children, they can also affect adults. The aims of this study were to describe the characteristics of DHG H3G34-mutant in adults and to compare them to those of established types of adult WHO grade IV gliomas. The characteristics of 17 adult DHG H3G34-mutant, 32 H3.3 K27M-mutant diffuse midline gliomas (DMG), 100 IDH-wildtype, and 36 IDH-mutant glioblastomas were retrospectively analyzed. Median age at diagnosis in adult DHG H3G34-mutant was 25 years (range: 19–33). All tumors were hemispheric. For 9 patients (56%), absent or faint contrast enhancement initially suggested another diagnosis than a high-grade glioma, and diffusion-weighted imaging seemed retrospectively more helpful to suspect an aggressive tumor than MR-spectroscopy and perfusion MRI. All cases were IDH-wildtype. Most cases were immunonegative for ATRX (93%) and Olig2 (100%) and exhibited MGMT promoter methylation (82%). The clinical and radiological presentations of adult DHG H3G34-mutant were different from those of established types of adult grade IV gliomas. Median overall survival of adult DHG H3G34-mutant was 12.4 months compared to 19.6 months (P = .56), 11.7 months (P = .45), and 50.5 months (P = .006) in H3.3 K27M-mutant DMG, IDH-wildtype, and IDH-mutant glioblastomas, respectively. Adult DHG H3G34-mutant are associated with distinct characteristics compared to those of established types of adult WHO grade IV gliomas. This study supports considering these tumors as a new type of WHO grade IV glioma in future classifications.

14 August 2020 in Cancer Research
Verified
Journal Article
Closed access
PDF file
FAFabien Almairac
Fabien Almairac
LTLaurent Turchi
Laurent Turchi
NSNathalie Sakakini
Nathalie Sakakini
DDDavid Nicolas Debruyne
David Nicolas Debruyne
SESarah Elkeurti
Sarah Elkeurti
TVThierry Virolle
Thierry Virolle
There is great interest in understanding how the cancer stem cell population may be maintained in solid tumors. Here, we show that tumor cells exhibiting stem-like properties and expression of pluripotency markers NANOG and OCT4 can arise from original differentiated tumor cells freshly isolated from human glioblastomas (GBM) and that have never known any serum culture conditions. Induction of EGR1 by EGFR/ERK signaling promoted cell conversion from a less aggressive, more differentiated cellular state to a self-renewing and strongly tumorigenic state, expressing NANOG and OCT4. Expression of these pluripotency markers occurred before the cells re-entered the cell cycle, demonstrating their capacity to change and dedifferentiate without any cell divisions. In differentiated GBM cells, ERK-mediated repression of miR-199a-3p induced EGR1 protein expression and triggered dedifferentiation. Overall, this signaling pathway constitutes an ERK-mediated "toggle switch" that promotes pluripotency marker expression and stem-like features in GBM cells. Significance: This study defines an ERK-mediated molecular mechanism of dedifferentiation of GBM cells into a stem-like state, expressing markers of pluripotency. See related commentary by Koncar and Agnihotri, p. 3195

24 July 2010 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
FBFanny BUREL-VANDENBOS
Fanny BUREL-VANDENBOS
MBMaxime Benchetrit
Maxime Benchetrit
CMCatherine Miquel
Catherine Miquel
DFDenys Fontaine
Denys Fontaine
RARomane AUVERGNE
Romane AUVERGNE
TVThierry Virolle
Thierry Virolle